公开(公告)号：WO2018005954A2

公开(公告)日：2018-01-04

申请号：PCT/US2017/040267

申请日：2017-06-30

Applicant: RESOLVE THERAPEUTICS, LLC

Inventor： POSADA, James, Arthur ,  PATEL, Sanjay ,  YU, Weihong ,  GABEL, Chris

IPC: A61K38/46

Abstract: The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Abstract translation: 本发明提供了具有增加的药代动力学性质的优化的双核酸酶融合蛋白。 本发明的优化的双链核酸酶融合蛋白与Fc结构域可操作地偶联的两个或更多个核酸酶结构域（例如RNase和DNase结构域）。 本发明还提供了治疗或预防与异常免疫应答有关的病症的方法。

公开(公告)号：WO2018005954A3

公开(公告)日：2018-01-04

申请号：PCT/US2017/040267

申请日：2017-06-30

Applicant: RESOLVE THERAPEUTICS, LLC

Inventor： POSADA, James, Arthur ,  PATEL, Sanjay ,  YU, Weihong ,  GABEL, Chris

IPC: C12N9/22 ,  A61K38/46

Abstract: The invention provides optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention comprise two or more nuclease domains, wherein a heterodimer is formed between a DNase operably coupled to an Fc domain and an RNase operably coupled to an Fc domain. The invention also provides uses of such binuclease fusion proteins in methods of treating or preventing a condition associated with an abnormal immune response.

公开(公告)号：WO2016069889A1

公开(公告)日：2016-05-06

申请号：PCT/US2015/058039

申请日：2015-10-29

Applicant: RESOLVE THERAPEUTICS, LLC

Inventor： POSADA, James, Arthur ,  GABEL, Chris

IPC: A61K38/46

CPC classification number: C12N9/22 ,  A61K38/00 ,  C07K2319/31

Abstract: The invention provides for hybrid nuclease-transferrin molecules with increased pharmacokinetic properties. The hybrid nuclease-transferrin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to a transferrin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Abstract translation: 本发明提供具有增加的药代动力学性质的杂交核酸酶 - 转铁蛋白分子。 本发明的杂交核酸酶 - 转铁蛋白分子具有可操作地偶联至转铁蛋白或其变体或片段的一个或多个核酸酶结构域（例如，RNA酶和/或DNA酶结构域）。 本发明还提供了治疗或预防与异常免疫应答有关的病症的方法。

公开(公告)号：WO2015066557A1

公开(公告)日：2015-05-07

申请号：PCT/US2014/063587

申请日：2014-10-31

Applicant: RESOLVE THERAPEUTICS, LLC

Inventor： POSADA, James, Arthur ,  GABEL, Chris

IPC: C12N9/22 ,  A61K38/46

CPC classification number: C12N9/22 ,  A61K38/00 ,  A61K38/465 ,  C07K14/765 ,  C07K2319/00 ,  C07K2319/31 ,  C12Y301/21001 ,  C12Y301/27005

Abstract: The invention provides for polypeptides having one or more nuclease domains (e.g., an RNase and/or DNase domain) with altered glycosylation, preferably operably coupled to a pharmacokinetic moiety, which optionally has altered glycosylation. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Abstract translation: 本发明提供具有改变的糖基化的一个或多个核酸酶结构域（例如，RNA酶和/或DNA酶结构域）的多肽，优选可操作地偶联至药代动力学部分，其任选具有改变的糖基化。 本发明还提供了治疗或预防与异常免疫应答有关的病症的方法。

公开(公告)号：WO2015066550A1

公开(公告)日：2015-05-07

申请号：PCT/US2014/063572

申请日：2014-10-31

Applicant: RESOLVE THERAPEUTICS, LLC

Inventor： POSADA, James, Arthur ,  GABEL, Chris

IPC: C12N9/22 ,  A61K38/46

CPC classification number: C12N9/22 ,  A61K38/00 ,  A61K38/465 ,  C07K14/765 ,  C07K2319/00 ,  C07K2319/31 ,  C12Y301/21001 ,  C12Y301/27005

Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

Abstract translation: 本发明提供具有增加的药物动力学性质的杂交核酸酶 - 白蛋白分子。 本发明的杂交核酸酶 - 白蛋白分子具有可操作地偶联到白蛋白或其变体或片段的一个或多个核酸酶结构域（例如，RNA酶和/或DNA酶结构域）。 本发明还提供了治疗或预防与异常免疫应答有关的病症的方法。